Non-surgical treatment options for pulmonary aspergilloma.
Amphotericin B
/ administration & dosage
Antifungal Agents
/ administration & dosage
Azoles
/ administration & dosage
Bronchial Arteries
Conservative Treatment
/ methods
Embolization, Therapeutic
/ methods
Female
Hemoptysis
/ etiology
Humans
Instillation, Drug
Male
Pulmonary Aspergillosis
/ complications
Aspergilloma
Aspergillosis
Bronchial artery embolization
Endobronchial
Intracavitary
Radiotherapy
Journal
Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
07
10
2019
accepted:
17
02
2020
entrez:
29
3
2020
pubmed:
29
3
2020
medline:
22
10
2020
Statut:
ppublish
Résumé
Aspergilloma, also known as mycetoma or fungus ball, is the most common manifestation of pulmonary involvement by Aspergillus species. The fungal ball typically forms within preexisting cavities of the lungs. Diagnosis requires both radiographic evidence along with serologic or microbiologic evidence of Aspergillus species involvement. While clinical features such as hemoptysis, chest pain, shortness of breath, cough, and fever are helpful in diagnosis, they are non-specific symptoms. Surgery is currently the mainstay of treatment for aspergilloma but is associated with considerable mortality and morbidity. Alternative options exist for patients who are poor surgical candidates and for those who prefer a less invasive treatment modality. Systemic treatment with amphotericin B is ineffective and is not recommended as a monotherapy, but systemic azoles is effective in approximately 50-80% of patients. Potential alternatives to surgery include intracavitary instillation or endobronchial administration of antifungal medication, as well as direct transbronchial aspergilloma removal. Bronchial artery embolization and radiotherapy are options to manage hemoptysis until definite eradication of the aspergilloma. More rigorous studies are needed to better establish non-surgical treatment paradigm for inoperable patients.
Identifiants
pubmed: 32217289
pii: S0954-6111(20)30043-3
doi: 10.1016/j.rmed.2020.105903
pii:
doi:
Substances chimiques
Antifungal Agents
0
Azoles
0
Amphotericin B
7XU7A7DROE
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
105903Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.